Massimo Breccia1, Robin Foà2. 1. Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it. 2. Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Via Benevento 6, 00161, Rome, Italy.
Abstract
PURPOSE OF REVIEW: Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid leukemia (CP-CML) patients has become a reality. Treatment-free remission (TFR) is the term that identifies success after discontinuation. RECENT FINDINGS: Several trials have demonstrated that with imatinib about 40% of patients discontinuing treatment in deep and stable molecular response remain disease-free. Second-generation TKIs have improved the rate of deep molecular responses and allowed to increase the percentage of patients attempting treatment discontinuation. We hereby review the current information based on the available published data and discuss the current suggestions on how to move TFR into the clinical practice.
PURPOSE OF REVIEW: Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid leukemia (CP-CML) patients has become a reality. Treatment-free remission (TFR) is the term that identifies success after discontinuation. RECENT FINDINGS: Several trials have demonstrated that with imatinib about 40% of patients discontinuing treatment in deep and stable molecular response remain disease-free. Second-generation TKIs have improved the rate of deep molecular responses and allowed to increase the percentage of patients attempting treatment discontinuation. We hereby review the current information based on the available published data and discuss the current suggestions on how to move TFR into the clinical practice.
Authors: Simone Claudiani; Jane F Apperley; Robert Peter Gale; Richard Clark; Richard Szydlo; Simona Deplano; Renuka Palanicawandar; Jamshid Khorashad; Letizia Foroni; Dragana Milojkovic Journal: Haematologica Date: 2017-05-11 Impact factor: 9.941
Authors: C Schütz; S Inselmann; S Saussele; C T Dietz; M C Mu Ller; E Eigendorff; C A Brendel; S K Metzelder; T H Bru Mmendorf; C Waller; J Dengler; M E Goebeler; R Herbst; G Freunek; S Hanzel; T Illmer; Y Wang; T Lange; F Finkernagel; R Hehlmann; M Huber; A Neubauer; A Hochhaus; J Guilhot; F Xavier Mahon; M Pfirrmann; A Burchert Journal: Leukemia Date: 2017-01-11 Impact factor: 11.528
Authors: Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker Journal: N Engl J Med Date: 2017-03-09 Impact factor: 91.245
Authors: A Hochhaus; S Saussele; G Rosti; F-X Mahon; J J W M Janssen; H Hjorth-Hansen; J Richter; C Buske Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Arnel Pallera; Jessica K Altman; Ellin Berman; Camille N Abboud; Bhavana Bhatnagar; Peter Curtin; Daniel J DeAngelo; Jason Gotlib; R Tanner Hagelstrom; Gabriela Hobbs; Madan Jagasia; Hagop M Kantarjian; Patricia Kropf; Leland Metheny; Joseph O Moore; Evelena Ontiveros; Enkhtsetseg Purev; Albert Quiery; Vishnu V B Reddy; Michal G Rose; Neil P Shah; B Douglas Smith; David S Snyder; Kendra L Sweet; Raoul Tibes; David T Yang; Kristina Gregory; Hema Sundar; Michael Deininger; Jerald P Radich Journal: J Natl Compr Canc Netw Date: 2016-12 Impact factor: 11.908